🔎 Trials Near Me

Beranda › Kanker Payudara Triple-Negatif › New Jersey › Edison

Uji klinis Kanker Payudara Triple-Negatif di Edison, NJ

11 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Edison (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • START New Jersey, East Brunswick · 6 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Menerima peserta
  • Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees, Voorhees Township · 5 mi jauhnya
Usia 30 ke atas · Wanita · Diperbarui 25 Sep 2026 · NCT02945579

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Menerima pesertaFase 3
  • Rutgers Cancer Institute of New Jersey ( Site 0076), New Brunswick · 3 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06966700

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Menerima pesertaFase 1
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06246968

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Menerima pesertaFase 2
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge · 15 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05570253

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Menerima pesertaFase 3
  • Rutgers Health, New Brunswick · 3 mi jauhnya
  • Regional Cancer Care Associates LLC, East Brunswick · 6 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05633654

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

Menerima pesertaFase 2
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauhnya
Usia 70 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07768436

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Menerima pesertaFase 2
  • Rutgers Cancer Institute of New Jersey, New Brunswick · 3 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT01042379

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Menerima pesertaFase 2
  • Memorial Sloan Kettering Basking Ridge, Basking Ridge · 15 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Feb 2026 · NCT03808337

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Menerima pesertaFase 2
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauhnya
Usia 18 ke atas · Wanita · Diperbarui 17 Feb 2026 · NCT04683679

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Menerima pesertaFase 2
  • Rutgers Cancer Institute of New Jersey, New Brunswick · 3 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Jun 2025 · NCT06568692

Uji klinis Kanker Payudara Triple-Negatif di kota lain

Studi lain di Edison

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.